

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

# **Differentially regulated proteins in breast cancer chemotherapy**

A thesis presented to Massey University in partial fulfilment of the requirement  
for the degree of Doctor of Philosophy in Biochemistry

Henning Koehn

2005

## **Acknowledgements**

First and foremost I would like to thank my supervisors Dr Kathryn Stowell and Dr Richard Isaacs for their support and encouragement during the course of my thesis work. Furthermore, I would also like to express my gratitude to Dr Kathryn Stowell for giving me the opportunity to undertake my studies in her laboratory.

I would also like to thank Massey University for its financial assistance by providing me with a doctoral scholarship.

Moreover, I would very much like to thank all those in the IMBS who have helped with so many different aspects of my research project. Also, I would like to express my appreciation to Dr Fran Wolber and Dr. Bruce Lockett for going the extra mile in helping me with my work.

I very much feel indebted to a few people who have helped make my stay in New Zealand so wonderful and a true Kiwi-experience, including Jamie, Santanu, Amram, Stu, Uwe, Verena, Mark, the Thirsties, and the members of the Twilight zone. Moreover, I am especially grateful to Mathias, Heiko, and Paul, who have proven that distance is not a barrier for friendship.

I would especially like to thank my parents for their relentless support, without whom this would have never been possible.

And a very special thank you goes to my best friend Melanie, for her patience, her help, and her friendship and making sure that the English language did not suffer undue distress in preparation of this thesis.

## **Abstract**

Intrinsic or acquired drug resistance of tumours is a major problem for successful therapy of breast cancer patients. The efficacy of doxorubicin, one of the most important and commonly used drugs in chemotherapy, can be severely compromised by a variety of unspecific mechanisms rendering tumours drug resistant. Little is known however, about the specific events taking place in response to doxorubicin treatment, which may repair doxorubicin-induced damage, leading to drug resistance.

Doxorubicin is a topoisomerase II poison, which interferes with topoisomerase II enzymes during DNA replication, resulting in DNA double-strand breaks. Topoisomerase II enzymes mediate the passage of DNA strands by introducing transient DNA breaks, and are essential for changes in DNA topology during replication. The DNA lesions induced by the combination of topoisomerase II and doxorubicin can be repaired by either non homologous end-joining or homologous recombination repair, as both pathways are specifically responsible for the repair of DNA double-strand breaks. The DNA-dependent protein kinase catalytic subunit in non homologous end-joining and Rad51 in homologous recombination repair are essential for each of these pathways. If it was possible to specifically target these proteins or other antagonistic mechanisms of doxorubicin-induced cell death, which may be activated in response to doxorubicin treatment, chemosensitivity of tumours could be restored and chemotherapy made more effective. Hence it was the purpose of this study to investigate proteome-wide changes in protein expression in response to drug treatment, as well as specifically analysing alterations in the protein levels of the DNA-dependent protein kinase catalytic subunit and Rad51.

Global changes in protein regulation of breast and breast cancer cells were investigated using mass spectrometric and electrophoretic analysis techniques. These experiments however, could not reproducibly identify any genuine drug-induced changes in protein levels, as only proteins of relatively high abundance could be analysed. Immunoblotting results however, showed that Rad51 was differentially regulated in a cell line- and drug dosage-dependent manner, while levels of the DNA-dependent protein kinase catalytic subunit remained largely unchanged. Furthermore, increased levels of topoisomerase II alpha protein were also detected. In addition, immunohistochemical analysis demonstrated that both Rad51 and the DNA-dependent protein kinase catalytic subunit could be independently overexpressed in breast tumours and therefore may represent potential targets for selectively enhancing chemosensitivity of breast cancers.

## Abbreviations

ABC	ATP-binding cassette
AcN	Acetonitrile
ATP	Adenosine triphosphate
ATPase	Adenosine triphosphatase
BSA	Bovine serum albumin
°C	Degrees Celsius
CAV2	Cavcolin-2
CCND1	Cyclin D1 encoding gene
cDNA	Synthetic DNA, generated from RNA
CHAPS	3-[(3-Cholamidopropyl)dimethylamino]-1-propanesulphonate
CHCA	alpha-cyano-4-hydroxycinnamic acid
dCTP	deoxycytidine-triphosphate
DIGE	Differential gel electrophoresis
DMEM	Dulbecco's modified eagle's media
DMSO	Dimethyl sulfoxide
DNA	Deoxyribonucleic acid
DNA-DSB	DNA double-strand break
DNA-PK	DNA-dependent protein kinasc
DNA-PKcs	DNA-dependent protein kinase catalytic subunit
DTT	Dithiothreitol
2DGE	Two dimensional gel elctrophoresis
EDTA	Ethylene diamine tetra-acetic acid
EGF	Epidermal growth factor
EGFR	Epidermal growth factor receptor
ER	Estrogen receptor
ESI	Electro spray ionization
FACS	Fluorescence activated cell sorting
FCS	Foetal calf serum
Fig.	Figure
HEPES	N-[2-hydroxyethyl]piperazine-N'-[2-ethane sulfonic acid]
HRR	Homologous recombination repair
HSP	Heat shock protein

ICAT	Isotope-coded affinity tagging
IEF	Isoelectric focusing
IPG	Immobilized pH gradient
kDa	Kilo Dalton
LC	Liquid chromatography
MALDI-MS	Matrix-assisted laser desorption ionisation mass spectrometry
MCE	Multi compartment electrophoresis
MCF12A	Mammary epithelial cell line
MCF7	Mammary epithelial carcinoma cell line
MDA MB 231	Mammary epithelial carcinoma cell line
MDR	Multidrug resistance
MDR1	Multidrug resistance gene
MEM	Eagle's minimal essential media
MRP	Multidrug resistance-associated protein
MS	Mass spectrometry
MS/MS	Tandem mass spectrometry
MudPIT	Multidimensional protein identification technology
MXP	Mitoxantrone resistance associated protein
Mw	Molecular weight
MWCO	Molecular weight cut-off
m/z	Mass per charge
NHEJ	Non homologous end-joining
OC	Over-confluent
PAGE	Polyacrylamide gel electrophoresis
PBS	Phosphate buffered saline
PBSE	Phosphate buffered saline plus EDTA
P-gp	P-glycoprotein
PIKK	Phosphatidylinositol 3-kinase-like kinase
PR	Progesterone receptor
p53	Tumour suppressor protein p53
R	resistant
RP-HPLC	Reversed-phase high performance liquid chromatography
RNase	Ribonuclease
RT	Room temperature

SCX	Strong cation exchange
SDS	Sodium dodecyl sulphate
SELDI-MS	Surface-enhanced laser desorption ionization mass spectrometry
T	Tyrosine
TBST	Tris buffered saline tween 20
TCA	Trichloroacetic acid
TEMED	N,N,N',N'-Tetramethylethylenediamine
TFA	Trifluoroacetic acid
TGF	Transforming growth factor
Topo II alpha	topoisomerase II alpha
T 25, 75, 300	Filter top tissue culture flask of 25, 75, 300 cm <sup>2</sup>
2-TCEP	Tris (2-carboxyethyl) phosphine
Xrcc4	X-ray repair cross-complementing protein 4)

## List of tables

	page
<b>Table 3.1:</b> Summary of candidate proteins	38
<b>Table 4.1:</b> Concentration methods	50
<b>Table 5.1:</b> Differentially regulated protein spots	75
<b>Table 6.1:</b> Nuclear and cytoplasmic staining of DNA-PKcs and Rad51 in MDA MB 231 cells	98
<b>Table 6.2:</b> Summary of H-scores of MDA MB 231 cells	99
<b>Table 6.3:</b> Summary of immunohistological staining of Rad51 and DNA-PKcs of 10 different tissue specimens	104

## List of figures

		page
<b>Figure 1.1</b>	ErbB2 signalling	3
<b>Figure 1.2</b>	Proposed structure and catalytic cycle of topoisomerase II	6
<b>Figure 1.3</b>	Mechanisms of drug resistance	10
<b>Figure 3.1</b>	SELDI analysis of a protein up-regulated in MCF7 cells	35
<b>Figure 3.2</b>	Gel view of differentially regulated proteins in MDA MB 231 and MCF12A cells	36
<b>Figure 3.3</b>	Peak flow diagram of candidate proteins of MCF7 and MDA MB 231 cells	37
<b>Figure 4.1</b>	2DGE gels of MDA MB 231 cells using 60 µg of protein	43
<b>Figure 4.2</b>	RP-HPLC prefractionation elution profiles	46
<b>Figure 4.3</b>	2D gels after sample prefractionation	47
<b>Figure 4.4</b>	Effect of prefractionation and narrow range IPG strip usage	48
<b>Figure 4.5</b>	Native and prefractionated samples on pH 4-7 strips	49
<b>Figure 4.6</b>	MALDI-MS BSA peak spectrum using the fast evaporation method	52
<b>Figure 4.7</b>	Peptide mass fingerprint	53
<b>Figure 4.8</b>	Protein identification	54
<b>Figure 5.1</b>	First set of 2D gels for MDA MB 231 cells	58
<b>Figure 5.2</b>	Potential candidates in MDA MB 231 cells	59
<b>Figure 5.3</b>	2D gels of 0 h batch 3 and 2 h batch 1	60
<b>Figure 5.4</b>	Candidate confirmation using samples 0 h batch 3 and 2 h batch 1	61
<b>Figure 5.5</b>	Reproducibility of control (0 h) samples from batches 1, 3, and 4	62
<b>Figure 5.6</b>	Samples taken 24 h after treatment of batches 1, 2, and 4	63
<b>Figure 5.7</b>	Drug-dosage-effect 24 h after 3, 25, and 50 µM doxorubicin treatment	64
<b>Figure 5.8</b>	Gel-to-gel reproducibility of sample "R"	65
<b>Figure 5.9</b>	Candidate spots as determined by Phoretix 2D software analysis	69
<b>Figure 5.10</b>	Inter-batch reproducibility	70
<b>Figure 5.11</b>	Influence of background on spot 403	71
<b>Figure 5.12</b>	Verification of genuine protein expression in spot 673	72
<b>Figure 5.13</b>	Expression analysis of spot 723	73
<b>Figure 5.14</b>	Expression analysis of spot 552	74
<b>Figure 6.1</b>	Cell cycle-dependent DNA DSB repair pathways	77

<b>Figure 6.2</b>	Schematic representation of NHEJ	79
<b>Figure 6.3</b>	Schematic representation of HRR	80
<b>Figure 6.4</b>	Densitometric analysis of MDA MB 231 extracts separated by SDS-PAGE	85
<b>Figure 6.5</b>	Immunoblot of MDA MB 231, MCF12A, and MCF7 cell protein extracts	85
<b>Figure 6.6</b>	Statistical analysis of temporal changes in protein expression	86
<b>Figure 6.7</b>	FACS results	88
<b>Figure 6.8</b>	Double thymidine block of MDA MB 231 cells	90
<b>Figure 6.9</b>	Cell viability assay	91
<b>Figure 6.10</b>	Immunoblot of MDA MB 231, MCF12A, and MCF7 cell protein extract	92
<b>Figure 6.11</b>	Statistical analysis of dosage-dependent changes in protein expression	93
<b>Figure 6.12</b>	FACS profiles for time course experiment	95
<b>Figure 6.13</b>	Immunohistochemical analysis of Rad51 and DNA-PKcs expression in MDA MB 231 cell blocks	97
<b>Figure 6.14</b>	Control blocks used for testing DNA-PKcs and Rad51 primary antibodies	100
<b>Figure 6.15</b>	Patient tissue samples probed against DNA-PKcs and Rad51 protein	101
<b>Figure 6.16</b>	Immunohistochemical staining of normal and tumour tissue	102
<b>Figure 6.17</b>	Rad51 and DNA-PKcs expression in specimen 17641/00G	103
<b>Figure 7.1</b>	Multi compartment electrophoresis	115
<b>Figure 7.2</b>	Multi dimensional protein identification technology	119
<b>Figure 7.3</b>	Isotope coded affinity tagging	121
<b>Figure 7.4</b>	Peptide quantification and identification using MS/MS	122
<b>Figure 7.5</b>	Detection limits for a 25 kDa protein	124

## Table of contents

	page
Acknowledgements	i
Abstract	ii
Abbreviations	iii
List of tables	vi
List of figures	vii
Table of contents	ix

### Chapter One: Introduction

1.1 Breast Cancer	1
1.2 Breast Cancer Treatment	1
1.2.1 Hormone Treatment	1
1.2.2 Immunotherapy of erbB2	2
1.3 Chemotherapy	4
1.3.1 Drug Categories	4
1.3.2 Topoisomerase II Poisons	5
1.4 Resistance Mechanisms	6
1.4.1 P-Glycoprotein Mediated Multi-Drug Resistance	6
1.4.2 Multi-Drug Resistance Associated Protein	7
1.4.3 Mitoxantrone Resistance Associated Protein	7
1.4.4 Glutathione-S-Transferase	8
1.4.5 erbB2	8
1.4.6 Topoisomerase II Alpha and Beta	8
1.5 New Therapeutic Agents and Reversal of Drug Resistance	11
1.5.1 Chemosensitizers	11
1.5.2 Tumour Suppressors and Proto-Oncogenes	11
1.6 Gene Expression Analysis	13
1.7 Posttranslational Protein Modification	13
1.8 Project Background	14
1.9 Aim of Project	15



2.2.5 Matrix-Assisted Laser Desorption Ionization	
Mass Spectrometry (MALDI-MS)	27
2.2.5.1 Farmer's Reagent Destaining	
(Gharahdaghi <i>et al.</i> , 1999)	27
2.2.5.2 Hydrogen Peroxide Destaining	28
2.2.5.3 In-Gel Protein Digestion	28
2.2.5.4 ZipTip <sup>®</sup> Sample Concentration	28
2.2.5.5 Dried Droplet Method	29
2.2.5.6 Fast Evaporation Method (Vorm <i>et al.</i> , 1994)	29
2.2.5.7 MALDI-MS Analysis	29
2.2.5.8 Peptide Mass Fingerprinting	30
2.2.5.9 Target Plate Maintenance	30
2.2.6 FACS (Fluorescence-Activated Cell Sorter) Analysis	30
2.2.7 Immunohistochemistry	31
2.2.7.1 Cell Blocks	31
2.2.7.2 Histological Staining	31

### **Chapter Three: SELDI-MS**

3.1 Surface-Enhanced Laser Desorption Ionization Mass Spectrometry (SELDI-MS)	33
3.2 Cell lines and protein extracts	33
3.3 Results	34
3.4 Protein Mass Identification	38
3.5 Discussion	39

### **Chapter Four: Establishing a Methodology for the Separation and Identification of Unknown Proteins**

4.1 Introduction	41
4.2 Optimisation for Two Dimensional Gel Electrophoresis	41
4.3 Two Dimensional Gels	42
4.4 Purification Strategies	43
4.5 Protein Prefractionation	44
4.6 Narrow Range pH Gradient Immobilized (IPG) Dry Strips	47
4.7 Peptide Mass Fingerprinting Using MALDI-MS	50

4.8 Discussion	54
----------------	----

## **Chapter Five: 2D gel electrophoresis**

5.1 Introduction and Strategy	57
5.2 Results	57
5.3 Summary	66
5.4 Discussion	66
5.5 Analysis of 2D Gels Using Phoretix <sup>®</sup> 2D Evolution Software	68
5.5.1 Reference Gel and Spot Comparison Analysis	68
5.5.2 Reproducibility Between Batches	69
5.5.3 Gel Analysis	71
5.5.4 Candidate Verification	72
5.5.5 Drug-Dosage Effect	73
5.5.6 Summary	74
5.5.7 Discussion	76

## **Chapter Six: DNA Double-Strand (DSB) Repair**

6.1 Introduction	77
6.2 Non-Homologous End Joining	78
6.3 Homologous Recombination Repair	79
6.4 DNA Damage Repair or Apoptosis?	81
6.5 Rad51 and DNA-PK Initiated Repair of Topoisomerase II Alpha Mediated DNA DSB	81
6.6 Aim	83
6.7 Experimental Design	83
6.8 Results	84
6.8.1 FACS Analysis	87
6.8.2 Synchronization of MDA, MCF7 and MCF12A Cells	88
6.8.3 Drug Dosage Effect	90
6.8.4 Dosage-Dependent FACS Analysis	94
6.9 Breast Cancer Immunohistochemistry	96
6.9.1 Staining of MDA MB 231 Cells	97
6.9.2 Tumour Sample Analysis	99

<b>6.10</b>	<b>Discussion</b>	<b>105</b>
-------------	-------------------	------------

## **Chapter Seven: Summary and Discussion**

<b>7.1</b>	<b>Project Aims</b>	<b>111</b>
<b>7.2</b>	<b>Project Results</b>	<b>111</b>
<b>7.3</b>	<b>Surface Enhanced Laser Desorption Ionisation Mass Spectrometry (SELDI-MS)</b>	<b>112</b>
<b>7.4</b>	<b>Two Dimensional Gel Electrophoresis (2DGE)</b>	<b>113</b>
<b>7.5</b>	<b>Sample Prefractionation Strategies</b>	<b>114</b>
	<b>7.5.1</b> Liquid Chromatography	<b>114</b>
	<b>7.5.2</b> Multi Compartment Electrophoresis	<b>114</b>
<b>7.6</b>	<b>Protein Visualisation and Staining Methods</b>	<b>116</b>
<b>7.7</b>	<b>Statistical Analysis</b>	<b>117</b>
<b>7.8</b>	<b>Alternative Methods for Proteome Analysis</b>	<b>118</b>
	<b>7.8.1</b> Multidimensional Protein Identification Technology (MudPIT)	<b>118</b>
	<b>7.8.2</b> Isotope-Coded Affinity Tagging (ICAT)	<b>119</b>
<b>7.9</b>	<b>The Future of “Old Fashioned” 2DGE and Proteomics</b>	<b>123</b>
<b>7.10</b>	<b>Post-Translational Modifications</b>	<b>125</b>
<b>7.11</b>	<b>Drug Treatment</b>	<b>126</b>
<b>7.12</b>	<b>DNA Repair Proteins</b>	<b>126</b>
	<b>7.12.1</b> Rad51	<b>127</b>
	<b>7.12.2</b> DNA-Dependent Catalytic Subunit (DNA-PKcs)	<b>129</b>
<b>7.13</b>	<b>Cell Cycle</b>	<b>130</b>
<b>7.14</b>	<b>Clinical Aspects</b>	<b>130</b>
<b>7.15</b>	<b>Conclusions</b>	<b>131</b>